The FDA on December 13, 2024, approved UNLOXCYT® (Cosibelimab-ipdl), a Programmed Death Ligand-1 (PD-L1) blocking antibody, for adults with metastatic Cutaneous Squamous Cell Carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. UNLOXCYT® is a product of Checkpoint Therapeutics, Inc.
Bottom Ad
Advertisement
Subscribe
